Modular atp study of the mcrm™ system meets primary safety and efficacy endpoints

Additional data from appraise atp trial reinforce modular therapy approach with emblem™ subcutaneous implantable defibrillator and empower™ leadless pacemaker marlborough, mass. , may 18, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced positive six-month results from the ongoing pivotal modular atp clinical trial of the mcrm™ system,* the first modular cardiac rhythm management (crm) system that consists of the emblem™ subcutaneous implantable defibrillator (s-icd) system and the empower™ leadless pacemaker (lp).
BSX Ratings Summary
BSX Quant Ranking